Dementia Drugs Market, By Drug Class (Cholinesterase Inhibitors, MAO Inhibitors, and Glutamate Inhibitors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) and By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Trends, Analysis and Forecast till 2029

Dementia is a disease related to the brain, which include various symptoms such as memory loss, difficulties with problem solving, thinking and language. Furthermore dementia is characterized with group of symptoms associated with a decline in memory and difficulties with thinking, problem-solving or language; severe enough to reduce person’s ability to perform daily activities. Alzheimer\'s disease is the most common and known type of dementia, in adults, accounts for 60% to 80% of overall dementia cases. Various other type of dementia includes Huntington’s disease, Frontotemporal dementia, Creutzfeldt- Jakob disease, Down’s syndrome, Dementia with Lewy Bodies, mixed dementia, Parkinson’s disease dementia, vascular dementia, among others.  

Growing incidence rate of Alzheimer’s disease among the global population, larger number of pipeline drugs in the treatment of dementia, along with substantial engagement of various key players in gaining regulatory product approval, will eventually drive the dementia drug market, in near future. For instance, in August 2017, Zydus Cadila has received U.S. Food and Drug Administration (FDA) approval to market Memantine Hydrochloride extended-release capsules (7 mg, 14 mg, 21 mg and 28 mg strengths) in the treatment of moderate to severe dementia of Alzheimer’s type.  

The global dementia drugs market has been segmented on the basis of drug class, distribution channel and region.

The drug class segment includes cholinesterase inhibitors, mao inhibitors, and glutamate inhibitors. Further the dementia drug market is segmented by distribution channel, which include hospital pharmacy, retail pharmacy and other distribution channel.

On the basis of region, the above market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is expected to hold major market share in the dementia drugs market, during the fiscal year 2018, owing to the higher number of dementia drug approvals in these region and availability of favorable reimbursement policies. Moreover, Asia Pacific region accounts to hold higher CAGR during the forecast period, due to the increasing presence of Alzheimer’s cases, combined with subsequent growing geriatric population, especially in the India and China.   

The key players operating in the global dementia drug market include Eli Lilly and Company, Cadila Healthcare Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Eisai Co., Ltd., Novartis AG, Forest Laboratories, Inc., and F. Hoffmann-La Roche.